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RESUMEN
Aceite de oliva y la hemostasia.
El aceite de oliva es un componente esencial de la dieta Medi-
terránea que puede explicar el bajo índice de enfermedad cardio-
vascular (CVD) en los países del sur de Europa. El aceite de oliva
(extra virgen) es una fuente de ácidos grasos monoinsaturados
(MUFA) y de compuestos fenólicos, de gran interés por sus efectos,
entre otros, sobre las lipoproteínas y los lípidos plasmáticos, su ca-
pacidad antioxidante y su papel en la expresión de factores relacio-
nados con la trombosis. En este capítulo se presenta un resumen
del conocimiento actual sobre la influencia derivada del consumo de
aceite de oliva (extra virgen) en el sistema hemostático y el riesgo
de CVD. Por ahora se sabe que dietas ricas en MUFA (aceite de
oliva) pueden atenuar la respuesta trombótica mediante la reduc-
ción de la agregación plaquetaria y de las concentraciones pos-
tprandiales del factor VII de coagulación (FVII). La trombosis es
un evento relevante en los ataques al corazón y el ictus, de mane-
ra que su modulación con la dieta puede constituir una forma ren-
table para la disminución de la incidencia de CVD en poblaciones
que consumen dietas enriquecidas en MUFA/aceite de oliva du-
rante largo tiempo.
PALABRAS-CLAVE: Aceite de oliva; Ácidos grasos monoin-
saturados; Hemostasia; Factor VII; Plaquetas; Fenólicos; Fibrinoli-
sis; Dieta Mediterránea.
SUMMARY
Olive oil and haemostasis.
Olive oil is a key component of the traditional Mediterranean
diet; a diet that may explain the low rate of cardiovascular disease
(CVD) in Southern European. (Extra virgin) Olive oil is a good
source of monounsaturated fatty acids (MUFA) and phenolic
compounds, both of which have been investigated for their effects
on plasma lipids and lipoproteins, measures of oxidation and
factors related to thrombosis. This issue aims to summarise the
current understanding of the effects of such dietary components
on the haemostatic system and subsequent risk of CVD. To date,
evidence suggests that diets rich in MUFA and thus in olive oil
attenuate the thrombotic response via a reduction in platelet
aggregation and in postprandial FVII levels. Thrombosis is a key
event in causing heart attacks and strokes, which if modulated by
diet could pose a cost-effective way of reducing CVD incidence in
populations that adhere to MUFA/olive oil-rich diets long-term.
KEY-WORDS: Olive oil; Monounsaturated fatty acids;
Haemostasis; Factor VII; Platelets; Phenolics; Fibrinolysis;
Mediterranean diet.
1. INTRODUCTION
Cardiovascular disease (CVD) is the main cause
of death in Europe accounting for over 4 million
deaths each year; about half of which are from
coronary heart disease (CHD) and nearly a third
from stroke (Rayner and Peterson, 2000). Mortality
rates vary between population groups, for example,
Southern European countries generally have lower
CHD death rates compared to the rest of Europe.
Death rates from stroke tend to be higher in Central
Grasas y Aceites
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and Eastern Europe than in Northern, Southern and
Western Europe. 
CVD is not only a major cause of death but also
contributes to ill health and disability. The number of
people suffering from CVD (e.g. angina) in some
European countries (e.g. UK) may even be rising
because of the ageing population and improvements
in treatment. Thus, the health care costs for the
(rising) number of CVD patients are economically
unsustainable. Consequently, public health
measures, such as improvements in diet and
physical activity levels are of paramount importance.
It is estimated that up to 30% of deaths from CHD
are due to unhealthy diets (National Heart Forum,
2002). The lower rate of CVD in Southern Europe
suggests a potential role of the traditional
Mediterranean diet in the prevention of CVD. In fact,
the Mediterranean diet has become a cultural model
for dietary improvement. It is characterised by the
use of olive oil as the major culinary fat, which is rich
in monounsaturated fatty acids (MUFA). In addition,
extra virgin olive oil contains a number of phenolic
compounds, for example, hydroxytyrosol and
oleuropein, which via their antioxidant and other
potent biological activities could partially account for
the observed healthful effects of the traditional
Mediterranean diet.
The effects of olive oil on blood lipids and CVD
risk have been reviewed elsewhere in this
supplement. The aim of this issue is to focus on the
effects of olive oil on haemostasis and subsequent
risk of CVD. The evidence for an effect of olive oil on
haemostasis is not as extensive as for lipids but is
interesting and warrants discussion. As a prelude to
this, the intricate haemostatic system will be
described and the associations between various
blood clotting factors and risk of CVD will be
reviewed.
2. THE HAEMOSTATIC SYSTEM: PLATELETS,
   COAGULATION AND FIBRINOLYSIS
The haemostatic system is essential for the
preservation of life, providing protection after wound
injury by controlling bleeding and playing a role in
tissue repair. The system comprises of the
endothelium of the blood vessel wall, platelets, the
coagulation and fibrinolytic systems (and their
co-factors) and their plasma inhibitors. 
The central step in stable clot formation is the
generation of the enzyme thrombin, which converts
the soluble protein fibrinogen to its insoluble
product, fibrin. The central role of thrombin is
illustrated by the fact that thrombin has more than 20
substrates in the haemostatic system, including
triggering the activation and aggregation of platelets.
The sequence of events that culminates in the
formation of a blood clot after injury can also occur
with rupture of an atheromatous plaque, resulting in
clot formation in the lumen of the vessel, a condition
known as thrombosis. This becomes problematic if
the lumen is partially or completely occluded
because blood flow to vital organs such as the heart
and brain is interrupted or obstructed. 
For the purpose of this review, the haemostatic
ystem will be divided into 3 phases: platelets,
coagulation and fibrinolysis. However, the events to
be described do not occur sequentially. In fact, tissue
damage activates both platelets and the coagulation
cascade simultaneously. Moreover, events are not
ranked in order of significance.
2.1. Platelets
Platelets are small cell fragments that are
produced by the disintegration of megakaryocytes,
the large precursor cells found in bone marrow
(Baboir and Stossel, 1990a). On release into the
circulation they circulate for approximately 9-12 days
and the normal platelet count varies widely (140-440
x 109/L).
The resting (unactivated) platelet has a discoid
shape with smooth, convex surface contours.
Random indentations are also present representing
sites of communication between channels of the
surface-connecting or open canalicular system, and
the exterior of the cell. It provides access to the
interior for plasma-borne substances and a route for
products of the ‘‘release reaction’’ (see below).
Platelet activation is accompanied by anatomical
changes including centralisation of the storage
granules, formation of pseudopodia and shape
change (from discs to spheres). Increased exposure
of fibrinogen binding sites is one of the earliest
events in platelet activation. Structural changes also
occur in other platelet membrane receptors, which
enables binding of other adhesive proteins such as
von Willebrand factor (vWF), vitronectin and
fibronectin.
The adhesion of platelets to exposed
subendothelial tissue following vascular injury is a
crucial part of the initial events of haemostasis.
Collagen is the main structural protein in the vessel wall
and it supports platelet adhesion (via receptors present
on the platelet) and activation. Once bound to platelet
receptors, both collagen and thrombin trigger platelet
synthesis of prostaglandins from cell membrane
arachidonic acid (AA, 20:4n-6). The product,
thromboxane A2 (TxA2) is a potent vasoconstrictor and
initiates the release reaction, thereby encouraging
aggregation of activated platelets.
2.1.1. The release reaction and platelet
       aggregation
Once adsorbed to the damaged site, platelets
swell and release many of their cellular constituents
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into the ambient blood. The dense granules contain
5-hydroxytryptamine (5-HT), noradrenaline, ATP,
ADP and calcium, which affect other platelets and
vasomotor responses. The a-granules contain a range
of proteins including platelet-derived growth factor
(PDGF), fibrinogen, Factor V, vWF, platelet factor 4 and
b-thromboglobulin. These influence the adhesion of
platelets to one another and to the endothelium as well
as other platelet properties. 
2.1.2. Regulation of platelet activation
To regulate the extent of the platelet response
and to prevent the inadvertent threat of platelet
thrombus and embolus formation a regulatory
mechanism is necessary. This is provided by the
surrounding endothelium, permitting blood flow
restoration. The platelets also contribute to the repair
mechanism by releasing PDGF and platelet-derived
endothelial growth factor (PDEGF), which
encourages repair of the endothelium.
Stimulated endothelial cells release inhibitory
agonists, which include certain prostaglandins
(PGI2), nitric oxide and adenosine. These
vasodilators inhibit platelet aggregation, promote
disaggregation, and inhibit platelet adhesion to the
endothelium. Interestingly, the opposing effects of the
prostanoids TxA2 (agonist) released by platelets, and
PGI2 (antogonist) released by endothelial cells, have
led to the concept that the extent of platelet recruitment
after vessel-wall injury is a function of the ratio of the
concentrations of these opposing factors. In addition
the chemical form and biopotency of the thromboxane
and prostacylcin formed by platelets and endothelial
cells is dependent upon the nature of the precursor
polyunsaturated fatty acid (PUFA) from which they are
derived. Dietary fat interventions that alter the
composition of the membrane fatty acid precursors
have the potential to alter platelet aggregation and
potentially thrombosis risk (BNF, 1992).
In summary, platelets circulate passively and do
not adhere to intact endothelium. However, in
response to agonists released from damaged vessel
walls (e.g. ADP, thrombin, serotonin), and following
the exposure of collagen, platelets rapidly undergo
the process of adhesion, shape change, secretion
and aggregation. Activation is a result of occupancy
by agonists of receptors on the platelet plasma
membrane that continues until the constricted lumen
of the small vessel is completely occluded by a loose
aggregate of platelets (Kroll and Schafer 1989). This
is transformed into a more definite plug by the
activation of the blood clotting mechanism.
2.1.3. Platelet function and risk of CVD
An increase in the sensitivity of platelets to
activation is strongly suspected in those at risk of
CVD. However, this has been difficult to prove using
established platelet function tests, e.g. aggregometry
because of the sensitivity of blood platelets to
handling. Nevertheless, marked reductions in coronary
events with aspirin use provide support for the role of
platelets in CHD (The anti-platelet trialists’
collaboration, 1994; 2002). Aspirin is now used
prophylatically for thrombotic disorders and is standard
treatment for patients with both cardiovascular and
cerebrovascular disease (George, 2000). Aspirin
irreversibly acetylates the amino terminal serine in
the active site of the enzyme cyclooxygenase,
resulting in the reduced formation of the cyclic
ndoperoxide intermediates and the final products of
AA metabolism, e.g. the platelet stimulating agent
TxA2 (Patrono et al., 1980). The effect persists for the
lifespan of the platelet. There are more drugs that
target platelet activation, e.g. clopidogrel prevents
platelet activation by ADP, an agonist that enhances
the activity of other platelet agonists (Payne et al.,
2002) and there are a number of agents that block
the platelet fibrinogen receptor, GPIIb/IIIa (Topol et
al., 1999).
2.1.4. Tests to measure platelet aggregation
Despite the scope of the methodology to
investigate platelet function, platelet aggregation
measured in whole blood or platelet rich plasma
(PRP) is routinely used because it is relatively simple
to perform. Moreover, it is a good measure of the
inhibition of platelet function, e.g. the administration
of aspirin or more potent antiplatelet drugs in vivo
results in demonstrable inhibition of the aggregation
response ex vivo to various agonists (Fitzgerald and
Barry, 1997). It is probably for this reason that such a
test has been used extensively to monitor platelet
status in both epidemiologic studies and clinical
trials. In fact, in dietary intervention studies it is the
most popular method of choice.
The application of this technique is based on the
premise that increased in vitro platelet aggregation
indicates an increased tendency for thrombogenesis
in vivo. It involves the addition of aggregating agents
(agonists) to whole blood/PRP and the extent of
aggregation will vary depending on the aggregating
agent and their concentration. Agonists that are
commonly used include ADP, thrombin, collagen,
TxA2, epinephrine and AA.
In a recent study neither the PRP nor whole blood
aggregometry techniques showed any predictive
power for myocardial infarction, but were better for
stroke (Elwood et al., 2001). However, earlier work in
a smaller cohort suggested that spontaneous
aggregation (without agonists) of platelets in those
with CVD was predictive of cardiac events and
mortality (Trip et al., 1990). Thus, the predictive value
of ex vivo platelet aggregation remains questionable.
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The lack of adequate and robust tests is a major
hindrance in determining the predictive power of
platelet function for CVD. There a number of other
tests to choose from, e.g. the analysis of eicosanoids
such as TxB2 (metabolic product of TxA2) and the
prostaglandin 6 keto F2a (metabolic product of
prostacyclin). Both can be measured in blood and urine
but their predictive power has not been elucidated yet.
A relation between these markers and the likelihood of
a subsequent event is a prerequisite for using them to
define a pro-thrombotic state (see below).
2.2. Coagulation cascade
The coagulation system is a proteolytic cascade
that is under very strict regulatory control provided by
positive and negative feedback loops (Figure 1). In the
healthy state, the pathway exhibits low-level basal
‘‘steady state’’ activity, which primes the system, holding
it ready for a response within seconds of injury. The liver
produces most of the clotting factors, and several of
them [factors II (FII), VII (FVII), IX (FIX), and X (FX)]
need vitamin K for production. Vitamin K is also needed
to produce protein C and protein S, which are natural
anticoagulants.
Upon injury, a series of linked reactions follows in
which a serine protease, once activated, is free to
activate its downstream substrate. By convention,
each clotting factor or zymogen of the coagulation
pathway is given a roman numeral, and its activated
form is donated by the subscript ‘‘a’’. Davie and
Ratnoff (1964) and Macfarlane (1964) originally
described these proteolytic transformations as a
waterfall sequence and cascade, respectively. This
process culminates in the generation of thrombin, the
nzyme that converts fibrinogen to fibrin, as well as
activating platelets. The action of thrombin on its
substrates is in a time- and concentration-ordered
manner to augment coagulation, bring it to completion,
prevent premature dissolution of the clot (fibrinolysis),
and return the system to its basal state (in press).
The conversion of prothrombin to thrombin is
mediated by FXa, which itself is activated either by
FVIIa of the extrinsic pathway or FIXa of the intrinsic
pathway. Thus, there are two alternate routes for the
generation of FX as well as the final common
pathway, which results in thrombin formation. Note
that these components of the overall pathway do not
act in isolation, for there are many cross-reactions
and back-reactions between them, which provide
auto-regulation.
2.2.1. The extrinsic and final common pathways
The extrinsic system is essentially the principal
initiating pathway of in vivo blood coagulation and
involves both blood and vascular elements. The
coagulation of plasma is triggered when a protein
called tissue factor or thromboplastin, which is
normally embedded in the plasma membrane of
cells, is exposed to blood. This occurs upon vessel
wall injury, which can be traumatic, inflammatory or
immunological in character (in press).
Factor VII then binds to exposed tissue factor and
undergoes a single cleavage to its active enzyme,
FVIIa. FIXa, FXa and FVIIa can also cleave FVII. A
tissue factor-factor VIIa complex forms, which activates
FX and FIX. Plasma FXa is the first molecule of the
common pathway and in association with FVa,
generates thrombin from prothrombin, which as noted
earlier has numerous substrates, (e.g. FV, FVIII, FXIII,
fibrinogen and platelets). Plasma FIXa, with its
co-factor vWf-FVIIIa, also activates FX.
Clot formation begins with the thrombin-catalysed
conversion of fibrinogen to fibrin. The clot is held
together by weak noncovalent forces at first, until the
action of FXIIIa, a cross-linking enzyme, resulting in
covalently held strands and a mature clot. The fibrin
matrix not only acts as a sealing of the wound, but
also facilitates the repair process by providing a
scaffold for cell invasion and angiogenesis.
2.2.2. The intrinsic pathway and the kallikrein-
       kinin (contact) system 
The kallikrein-kinin system (previously referred to
as the contact system) comprises of factor XII (FXII),
TF
XII
IX
IXa
Prothrombin
(II)
X
Xa
Thrombin (IIa)
Fibrinogen
Fibrin
VII
complex
TF VIIa
complex
Protein Cactivator complex
Protein C
Cell
surface
Va
VIIIa
Protein S
Intrinsicsystem
Extrinsic system
TM
XIIa, IXa,
Xa, thrombin
Cell
surface
Phospholipid surface membranes
XIIa
XI
XIa
Prekallikrein
HMK
-ive charged surfaces
HMK, high-molecular-weight kininogen
TM, thrombomodulin
       , coagulant activity
       , anticoagulant activity
Subscript “a” denotes the enzyme product of the zymogen precursor protein
   , FX converting complex and prothrombin converting complex, respectively
Figure 1
The Coagulation Pathway (classical description). In the classical
description, exposure of blood to non-membranous surfaces
and of negative charge activates the intrinsic pathway. The
extrinsic pathway is activated when blood contacts with cell
membranes exposing tissue factor (TF). The sequential
proteolytic transformations are dependent of phospholipids
and take place on cell membrane surfaces.
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factor XI (FXI), prekallikrein (PK) and high molecular
weight kininogen (HMWK). For many years, it was
thought that these proteins interact upon binding to
negatively charged surfaces, such as collagen,
heparans, and free fatty acids, which results in
several activation products (e.g. FXIIa and FXIa) and
ultimately the activation of FX. More recently, a new
hypothesis has emerged suggesting that HMWK,
which circulates in plasma in a complex with PK and
FXI, binds a multiprotein receptor complex on
endothelial cells. This results in the conversion of PK
to kallikrein, by the membrane-expressed enzyme
prolycarboxypeptidase (Schmaier, 2002). Kallikrein
autodigests its receptor, liberating the vasoactive,
proinflammatory mediator bradykinin, and activates
FXII (Shariat-Madar et al., 2002). Increased levels of
FXII activate FXI. The action of FXIa and thrombin
(via feedback) generate FIXa, which, in concert with
its co-factor (vWf-FVIIIa) activates FX, which feeds
into the common pathway already described.
2.2.3. Inhibitors of blood coagulation
Coagulation inhibitors are necessary to ensure
that thrombin generation remains limited and
localised. In summary, for every procoagulant
response, there is an anticoagulant mechanism.
Tissue factor pathway inhibitor (TFPI) neutralises the
extrinsic pathway; heparin is a cofactor for
antithrombin III, which inhibits all of the serine
proteases of the clotting cascade (except FVIIa);
alpha-1 antitrypsin is an inhibitor of the
kallikrein-kinin system of coagulation; and protein C
is converted to its activated form by endothelial
bound thrombomodulin, and once activated, works
with Protein S to inactivate the cofactors FVa and
FVIIIa. There are more circulating and cell-bound
proteins that inhibit coagulation but they are not
discussed in this review because of the scarity of
data in relation to CVD risk and intervention by diet.
2.3. The Fibrinolytic system
The fibrinolytic mechanism prevents excessive
fibrin accumulation by promoting local dissolution of
thrombi and promoting wound healing by
re-establishment of blood flow. Thus, the breakdown
of the fibrin clot by plasmin is necessary to make way
for repair of the damaged vessel.
Fibrinolysis involves the conversion of
plasminogen to plasmin by the action of plasminogen
activators, e.g. tissue plasminogen activator (t-PA)
and urokinase plasminogen activator (u-PA)
(Marckmann, 1995). The activities of plasmin and
t-PA, are regulated by alpha2-antiplasmin and
plasminogen activator inhibitor-1 (PAI-1),
respectively (Mann, 1997), thus preventing excess
fibrinogen degradation by plasmin. Both PAI-1 and
alpha2-antiplasmin also inhibit activated protein C,
thus increasing thrombin generation, platelet
aggregation and fibrin formation. Thrombin
activatable fibrinolysis inhibitor (TAFI) (also known as
procarboxypeptidase B) is a recently discovered
inhibitor of fibrinolysis. As the name suggests TAFI is
activated by high concentrations of thrombin
generated after clot or thrombus formation. In
addition, low concentrations of thrombomodulin
augment the generation of activated TAFI. The
digestion of a clot by plasmin results in fibrin-split
products, which are themselves, potent inhibitors of
clotting (Babior and Stossel, 1990b).
In summary, the clotting cascade is a series of
linked biochemical reactions that result in the
formation of a durable fibrin clot. Blood coagulation is
initiated by membrane bound tissue factor, and is
amplified through the intrinsic pathway by
mechanisms that provide crosstalk and feedback.
Virtually all of the coagulation reactions take place
on activated cell surfaces and, in some cases,
accelerate by the presence of a cofactor (FVa and
FVIIIa). Haemostasis can be considered a finely
tuned balance between procogulant and
anticoagulant forces. Clinical phenotypes, namely
bleeding or thrombosis, arise when the scale is
tipped towards one side or the other (Aird, 2003).
3. PROTHROMBOSIS AND RISK OF CVD
A ‘‘pro-thrombotic’’ state encompasses a change
in any component of the haemosatic system that
raises the risk of thrombosis e.g. increased
sensitivity of platelets to activation or an imbalance in
thrombin’s diverse roles. In other words, the
pro-thrombotic state exists when there is an
imbalance between coagulability and fibrinolytic
capacity that favours fibrin deposition and clot
formation. Although a single measure of the
pro-thrombotic state would be ideal, it does not exist.
Clinical markers of prothrombosis have included
raised levels of fibrinopeptide A (a marker of
thrombin’s action on fibrinogen) and decreased
levels of D-dimer (a marker of fibrin turnover). At
present, these measures are impractical for
epidemiological studies. Instead, markers of platelet
activation, changes of the vascular endothelium
(t-PA and PAI-1) and the clotting cascade have been
investigated as potential risk factors for CVD. It
should be recognised that a pro-thrombotic state
could exist without necessarily leading to thrombosis
in the same way that not everyone with a high blood
cholesterol level suffers a myocardial infarction.
Risk factor modificiation serves to ameliorate the
pro-thrombotic state and reduce atherothrombotic
events. The established haemostatic risk factors that
are associated with CVD and modifiable by
MUFA-rich diets such as olive oil are discussed
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below. Only data relating to human studies will be
discussed.
4. SPECIFIC HAEMOSTATIC RISK FACTORS
   AND CVD
4.1. Factor VII
Results from the first Northwick Park Heart Study
(NPHS) conducted in the 1970s in England provided
the impetus for further investigation into the role of
FVII in CHD. Plasma FVIIc, a functional measure of
the combination of circulating concentrations of FVII
and FVIIa, was identified as a marker of risk of fatal
(but not non-fatal) CHD (Meade et al., 1986).
Surprisingly, NPHS-II undertaken in the 1990s did
not identify FVIIc as a risk factor, which could be
explained by the decrease in dietary fat intake over
the intervening years (Cooper et al., 2000). Other
studies have failed to show FVIIc as a risk factor for
CHD (Tracy et al., 1999), which indicates that raised
FVIIc is not a consistent CHD risk factor.
Typically, FVIIa rises postprandially but this
seems to have no influence on the basal generation
of thrombin (Bladbjerg et al., 2000). However, since
FVIIa-tissue factor complex is responsible for the
initiation of the coagulation cascade, increased
generation of FVIIa in the postprandial state would
increase the potential for thrombin production in the
event of plaque rupture with exposure of tissue factor
to blood (Silveira, 2001).
4.2. Fibrinogen
Many studies have found fibrinogen to be a
predictor of CHD (Meade et al., 1993; Mann, 1997;
Heinrich et al., 1994; Cooper et al., 2000; Tracy et al.,
1999) and it is also an established risk factor for
thrombotic stroke (Wilhelmsen et al., 1984). Yet the
precise pathophysiological relation of fibrinogen and risk
of CHD is unknown. Atherosclerosis could secondarily
cause an increase in fibrinogen because it is an
acute-phase protein and fibrinogen has been associated
with changes in other acute phase proteins including
C-reactive protein (CRP) (Kuller et al., 1996). Either way,
increased fibrinogen concentrations could adversely
affect plasma viscosity and platelet aggregability. 
Fibrinogen concentration is associated with several
other cardiovascular risk factors; it increases with age,
BMI and smoking and is elevated in postmenopausal
women. Physical activity is inversely associated with
fibrinogen and females have higher levels than males
(Meade et al., 1985; 1979).
4.3. Fibrinolytic factors
Indirect measures of fibrinolysis (e.g. dilute blood
clot lysis time) have shown positive associations with
CHD (Meade et al., 1993). More direct measures of
hypofibrinolysis (using t-PA antigen, PAI-1 antigen and
activity) are also positive risk factors for CHD (Hamsten
et al., 1985; 1987; Ridker t al., 1993). PAI-1 has been
positively associated with risk factors associated with
syndrome X, namely central obesity, high tr lyceride
concentrations, low HDL-cholesterol, hyperglycaemia
and low physical activity (Dawson and Henney, 1992).
Finally, Ridker et al. (1994) have reported that the
mean concentration of t-PA antigen is higher among
men at increased risk of stroke than in those not at
risk.
Overall, the evidence for associations with CVD is
strongest for fibrinogen. Intervention by diet has
focused on FVII, with less emphasis on fibrinogen
and fibrinolytic factors.
4.4. Tests to measure coagulation and
     fibrinolytic factors
In order to obtain reproducible results,
haemostatic factor assays need to be performed with
considerable care. One of the main concerns is
prevention of in vitro artifacts that can significantly
alter the assay results. These include the quality of
the venepuncture, the sample processing
procedures, choice of anticoagulant and plasma
storage conditions (Bauer, 1993). Considerations of
these factors are a prerequisite for coagulation
studies. 
Discrepancies in results between laboratoires
can sometimes be ascribed, at least in part, to the
choice of method employed. Although assays for
FVIIa, FVII antigen (FVIIag), fibrinogen and t-PA are
now routine, there has been considerable debate
about the best method to use for FVII analysis.
Furthermore, there was some concern about the
considerable inter-laboratory variation in PAI-1
levels determined with commercial kits, especially
for assays measuring activi y levels (Marckmann,
1995).
5. THE MEDITERRANEAN DIET
There is a consensus on what constitutes a
traditional Mediterranean diet: plenty of fresh
vegetables, fruit, grains and olive oil with moderate
consumption of wine (mainly red wine) and dairy
products (mainly cheese). However, there is
considerable debate about the nutrients responsible
for the purported health effects of such a diet. The
low saturated/high MUFA content has received
considerable attention. Olive oil contains 73%
MUFA of which all but 1% is oleic acid (18:1n-9). It
contains 14.3% saturated fatty acids (SFA) and
8.2% PUFA (MAFF, 1998). Rapeseed oil contains
59% MUFA, 7% SFA, 29% PUFA, and has been
used in many intervention studies to investigate the
benefits of MUFA-rich diets, particularly in Northern
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Europe because it is more economical than olive
oil. Nevertheless, it is assumed that the effects
observed with rapeseed oil would apply to diets
rich in olive oil.
Previous research concerning protective
cardiovascular properties of olive oil has focused on
the beneficial consequences on blood cholesterol
levels of substituting dietary SFA with oleic acid.
However, the lower rate of CHD in Southern Europe
compared to Northern parts could be attributable, at
least in part, to the anti-thrombotic effects of
MUFA-rich diets. Of course, it is also possible that
antioxidants and other phytochemicals have a role to
play in the contribution to CVD risk but the following
section will focus on the evidence for an effect of
MUFA-rich diets on haemostatic factors.
5.1. Platelets and MUFA
It is perhaps not surprising that dietary fats, which
may alter the composition of the platelet membrane,
would affect their function since many of the events
that occur during platelet activation are membrane
dependent. However, the data illustrating changes in
platelet aggregation in response to changes in fat
composition are equivocal. Sirtori et al. (1986)
reported significant decreases in aggregation in
response to collagen and AA when olive oil diets
containing 17.5% energy as MUFA were
administered for 8 weeks. Likewise, Barradas et al.
(1990) found that olive oil supplementation (21g/day
for 8 weeks) to healthy volunteers reduced platelet
aggregation induced by ADP and collagen. More
recently, in a population of young healthy adults,
consumption of a MUFA-enriched diet in comparison
to a diet rich in SFA, resulted in a significant
decrease in whole blood platelet aggregation at 8
weeks in response to ADP, collagen and AA, which
was maintained at 16 weeks in response to ADP
(Figure 2; Smith et al., 2003). Importantly the source
of MUFA in this study was based on refined olive and
rapeseed oil, eliminating the possibility that these
effects were due to other constituents different to
triglycerides. Notably the effects observed on whole
blood platelet aggregation are not large, but they may
be important when translated to whole population
shifts in SFA and MUFA intakes. In contrast,
McDonald et al. (1989), Freese et al. (1994) and
Vicario et al. (1998) found no significant change in
aggregation when the MUFA content of the diets was
increased, whereas Mutanen et al. (1992) and
Turpeinen et al. (1998) found that oleic acid- and
linoleic acid-rich diets enhanced ADP- and
collagen-induced aggregation respectively, when
compared to diets rich in SFA. Discrepancies
between results may relate to study design, the
MUFA content of the diet, dietary control, the
concentration and types of agonist employed and
study duration. The weight of the evidence suggests
potential modest beneficial effects of MUFA-rich
diets, such as olive oil on platelet aggregation. 
5.2. Mechanism of action of MUFA on platelets
At least two processes are likely to be involved for
fatty acids to regulate platelet function; modulation of
the pool of precursor fatty acids and their
competitors, with subsequent effects on eicosanoid
metabolism; and a change in cell membrane fluidity
as a result of which the activity and/or efficiency of
receptors can be modulated (Hornstra and Rand,
1986; Mutanen, 1997).
In addition, there is evidence both in favour of
(Carvalho et al., 1974; Aviram and Brook, 1982;
Stuart et al., 1980) and in contrary to (Joist et al.,
1979) the idea that the plasma lipoprotein
environment might influence platelet reactivity. In
support of this theory, cholesterol-lowering drugs
have been shown to reduce platelet activation
markers significantly, in addition to reductions in total
and LDL-cholesterol levels (Huhle et al., 1999;
Hussein et al., 1997). There is also evidence that low
levels of oxidation in LDL enhance platelet activity
(Siess et al., 1999). An enriched MUFA diet prevents
LDL oxidative modifications more than an enriched
PUFA diet. Finally, the lipid (e.g. cholesterol) and fatty
acid composition of platelets appears to be different
in patients with CVD compared to healthy controls
(Noula et al., 2000). Thus, improvements in the
plasma lipid profile in response to MUFA-rich diets
could benefit platelet reactivity.
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Figure 2
Changes in whole blood platelet aggregation in response to
ADP (10 mM), collagen (4  mg/mL) and arachidonic acid
(AA) (1 mM) after 8 weeks and 16 weeks of dietary MUFA
intervention. Mean values and SEM (n = 29).
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5.3. Effects of MUFA on fasting haemostatic
     factors 
5.3.1. Fibrinolytic factors
Few studies have been undertaken to determine
the effects of MUFA on fibrinolytic factors. The
Uppsala Longitudinal Study reported that PAI-1
activity was positively related to habitual MUFA and
PUFA intake, but not to SFA consumption (Byberg et
al., 2001). However, favourable effects on PAI-1
levels have been suggested based on intervention
studies (Lopez-Segura et al., 1996; Temme t al.,
1999; Avellone t al., 1998). Yet other work indicates
no benefit from MUFA-rich diets on PAI-1 levels
(Tholstrup et al., 1999; Turpeinen and Mutanen,
1999) and t-PA activity (Lopez-Segura et al., 1996;
Tholstrup et al., 1999; Smith et al., 2003). Studies
also show that MUFA-rich diets have no effect on
TFPI, Fragment 1+2 (Larsen et al., 1999),
plasminogen or alpha-2 antiplasmin (Lopez-Segura
et al., 1996; Temme et al., 1999). Thus far,
intervention studies clearly show no adverse effects
from MUFA-rich diets on fibrinolysis. Beneficial
effects may occur in some situations but for the
general population, improvements in fibrinolytic
markers are not guaranteed. To obtain definite
answers, long-term prospective studies with clinical
end points are ideal, but expensive and impractical. It
is possible that intervention studies have not used
the best marker for fibrinolytic activty, which provides
the impetus for further work to investigate the extent
of an effect of MUFA-rich diets, such as those rich in
olive oil on fibrinolytic factors. 
5.3.2. Fibrinogen
Of all the haemostatic factors linked with CVD, the
evidence is probably strongest for fibrinogen yet it
appears to be unchanged by dietary unsaturated
fatty acids of which most studies concentrated on
fish oil enrichment (BNF, 1992). Similarly, recent
dietary intervention studies using MUFA-rich diets
found no change in fibrinogen concentration
(Turpeinen and Mutanen, 1999; Smith et al., 2003;
Avellone et al., 1998).
5.3.3. Factor VII
There have been a number of studies
investigating the effects of dietary fat on FVII,
particularly because of the positive association
between FVII and plasma TAG concentration in the
non-fasting and fasting states (Mitropoulos et al.,
1989). With improved methods of measurement, it
has become clear that diets habitually rich in fat
result in an increase in the concentration of fasting
FVIIag (Miller et al., 1995). In the majority of studies,
different fatty acid classes (SFA, MUFA, PUFA, trans)
do not significantly affect the concentration of fasting
FVII levels (Heinrich et al., 1990; Foley et al., 1992;
Marckmann et al., 1998; Finnegan et al., 2003;
Sanders et al., 2003). Similarly, a more recently
completed study involving young healthy subjects
who consumed a SFA-rich diet for 8 weeks
immediately followed by a MUFA-rich diet for 16
weeks found no change in fasting FVIIc or FVIIag
levels (Smith et al., 2003). However, Lindman and
colleagues (2003) report higher levels of fasting
FVIIa after a high SFA diet compared a
high-unsaturated fatty acid diet; each diet was
consumed for 3 weeks in a cross-over design.
Moreover, there are a few studies suggesting
beneficial effects on fasting variables after
MUFA-rich diets. Turpeinen and Mutanen (1999) and
Temme et al. (1999) found more favourable effects
on FVII levels with oleic acid than linoleic acid- and
SFA-rich diets, respectively. Larsen t al. (1999)
found a reduction in fasting FVIIc and FVIIa following
consumption of olive oil and rapeseed oil-enriched
diets compared to a habitual diet rich in SFA. Finally,
a ‘‘Mediterranean type’’ diet produced significant
reductions in fasting FVIIc in those living in urban
areas whereas there were significant increases in
FVIIc in the rural population when they consumed
the ‘‘urban type’’ diet (Avellone et al., 1998).
Obviously the effects of the latter study cannot be
attributed to the use of olive oil but suggest benefits
of a Mediterranean style diet on haemostasis. Thus,
there is a consensus that MUFA-rich diets do not
have unfavourable effects on haemostasis and for
the population at large the current evidence suggests
a neutral role of MUFA-rich diets on fasting
haemostatic variables.
However, Zilversmit (1979) made the point that man
is mostly non-fasting and that postprandial biochemical
events have a strong impact on human physiology,
including atherogenesis and thrombogenesis. The
effects of MUFA on postprandial activation of FVII
after test meals rich in MUFA (acute) and after
habitual diets rich in MUFA (chronic) appear
conflicting and warrant discussion.
5.4. MUFA-rich test meals and FVII
The transient increase seen in FVIIc after a fat
rich meal is due mainly to a rise in the concentration
of FVIIa (Miller et al., 1991; Silveira et al., 1994;
Salomaa et al., 1993). The composition of dietary fat
can influence postprandial levels of FVII.
Earlier work demonstrated that fats rich in MUFA
do not differ from fats rich in PUFA or SFA with
regard to acute effects on postprandial FVII. Freese
and Mutanen (1995) observed no differences
between rapeseed oil, sunflower oil, and butter oil
with regard to postprandial FVIIc and plasma
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triglyceride responses. Larsen t al. (1997) found
similar increases in plasma triglycerides, FVIIc and
FVIIa after test meals rich in olive oil, rapeseed oil,
palm oil, sunflower oil, or butter. Roche and Gibney
(1997) specifically investigated the effect of meals
with varying MUFA content (12%, 17% and 24% of
energy) on postprandial FVII activation. Although
there was no difference in the extent of activation of
factor VIIc between meals, peak postprandial factor
VIIa was attained significantly earlier following the
high-MUFA meal compared with the low-MUFA meal
and fasting activity levels were quickly restored. The
implications of this pattern of FVII activation are not
clear but could attribute to a less thrombotic state. In
contrast, concern was expressed about the effects of
MUFA on CVD after more pronounced responses of
FVIIc to test meals rich in MUFA compared to meals
rich in SFA were reported by Oakley t al. (1998). In
support of the latter study, a high-palmitic acid meal did
not lead to any postprandial change in FVIIc whereas it
was significantly increased 6 hours from fasting after a
high-oleic acid meal (Sanders t al., 1999). Moreover,
the increase in FVIIa concentrations after the
high-palmitic acid meal was half that seen after the
high-oleic acid meal.
Initially these two studies may cause alarm with
respect to the proposed benefits of olive oil and diets
rich in MUFA on haemostasis. However, repeat test
meal studies do not convey any information about
the effects of habitual diets; rather they divulge
important mechanistic information. Therefore,
caution should be exercised when interpreting the
results of test meal studies in terms of implications
for public health. Furthermore, the findings of Oakley
et al. (1998) and Sanders et al. (1999) are in contrast
with more recent reports that demonstrate lower
levels of postprandial FVIIa when subjects consume
background diets that are high in MUFA (discussed
below).
5.5. MUFA-rich diets and postprandial FVII
Interest in diets habitually rich in MUFA was
re-ignited when the postprandial response to dietary
fat was found to be different between Northern and
Southern European populations. For example,
Southern Europeans experienced a more rapid peak
in postprandial triglyceride levels but concentrations
quickly returned to preprandial levels (Zampelas et
al., 1998). Moreover, although no significant effect of
test meal composition was found (SFA v’s MUFA)
FVIIc was significantly greater 8 hours
postprandially in Northern Europeans than in
Southern Europeans (Zampelas et al., 1998). The
difference in response was also observed in an
8-weeks crossover dietary intervention study where
approximately 40% of SFA were replaced with
MUFA (Roche et al., 1998). In response to a
standard olive oil test meal postprandial FVIIa and
FVIIag were significantly lower after the MUFA diet
than after the SFA diet. Data from Larsen et al.
(1999) contribute to the potential beneficial effect of
MUFA-rich diets. Diets rich in olive oil, rapeseed oil
and sunflower oil were administered for 3-weeks
periods. The olive oil diet was associated with lower
nonfasting mean and peak concentrations of FVIIa
than was the sunflower oil diet. Although not
statistically significant, nonfasting mean and peak
concentrations of FVIIa also tended to be lower after
the olive oil diet than after the rapeseed oil diet. A
long-term dietary intervention study (16 weeks) has
confirmed the effects described above (Silva et al.,
2003). Compared with an SFA-rich diet, consumption
of a MUFA-rich diet for 16 weeks was associated
with significantly lower postprandial FVIIc; the
response of FVIIa was also lower but did not reach
statistical significance. The beneficial effects of
adopting a MUFA-rich diet were sustained long-term,
which illustrates that there is no attenuation through
adaptation.
Taken together, these data demonstrate
beneficial effects of diets rich in MUFA, e.g. olive oil
and contribute to the explanation for lower rates of
CHD in countries whose diets are habitually rich in
MUFA, such as Southern Europe.
5.6. Mechanism of action of MUFA on FVII
     activation
The mechanism whereby dietary fat leads to
activation of FVII has been thoroughly investigated
but remains uncertain (in press). Advancement in
this area was hampered in earlier years because of
the number of different tests used to measure FVII
both between and within studies. Nevertheless,
hypotheses evolved from in vitro work, which in some
cases were refuted once human studies were
performed (Miller et al. 1996). It does appear from
studies in vivo with specific coagulation factor-deficient
patients that FIX is essential for the postprandial
activation of FVII (Silveira, 2001). Furthermore, the
idea that the type of lipoprotein particle and their
components may be related to FVII activation
(Mitropoulus et al., 1989) was supported in a human
dietary intervention study that suggests chylomicron
number and/or particle size is a determinant of FVII
activation (Silva et al., 2003). In brief, MUFA-rich
diets resulted in the formation of a smaller number of
larger chylomicron particles and attenuated
postprandial FVII activation. However, the
mechanism by which lipoproteins could support FVII
activation is not clear. It has also been hypothesised
that the differential affinity of fatty acids for
peroxisome proliferator activated receptor alpha
(PPARa) (Lin et al., 1999), nuclear hormone
receptors that play critical roles in regulating lipid
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metabolism, may help explain some of the
differences in FVII activation, at least in the acute test
meal situation.
5.7. Other components in olive oil
The proposed benefits of (extra virgin) olive oil
may also relate to the presence of antioxidants such
as phenolic compounds and vitamin E.
5.7.1. Phenolic compounds
The effects of certain polyphenols in red wine,
such as resveratrol and quercetin, have been widely
investigated to determine the relationship between
dietary phenolic compounds and the decreased risk
of cardiovascular diseases in large population
groups. However, the effects of polyphenols
contained in other foods, such as extra virgin olive oil,
have received less attention and little information
exists regarding the biological activities of the phenol
fraction in extra virgin olive oil.
The type and amount of phenolics present in
extra virgin olive oil will depend on the origin of olives
and processing technique employed. Olive oils tend
to be classified into refined (without phenolic
compounds), common (with low phenolic content) or
extra virgin (with high phenolic content). The major
phenolic compounds in extra virgin olive oil are
oleuropein, hydroxytyrosol and tyrosol but at least 30
phenolic compounds can be present (Tuck and
Hayball, 2002; see also issue 1).
Refined olive oil contains less phenolic
compounds because during its production a large
fraction of bioactive compounds present in olives is
lost in mill waste-water. Because of the link between
flavonoids and a reduced risk of CHD, and to reduce
any ecological problems linked to the disposal of such
waste, different procedures are under investigation for
the recovery of the active components of olive mill
waste-water (www.flair-flow.com/health-docs/ffe59703.html).
Although unpublished yet, this project has shown
that hydroxytyrosol administered as a capsule
reduces platelet aggregation. It is unclear at present
whether lower doses, such as those in extra virgin
olive oil produce the same effects. 
Petroni et al. (1995) published the first evidence
that components of the phenolic fraction of extra
virgin olive oil inhibit platelet function and eicosanoid
formation in vitro. 2-(3,4-di-hydroxyphenyl)-ethanol
(DHPE), a phenol component of extra virgin olive
oil decreased platelet agregation induced by ADP
and collagen, and TxB2 production by collagen
and thrombin-stimulated PRP. Oleuropein was
less active in reducing PRP aggregation. In a
recently published study two isochromans
[1-(3’-methoxy-4’-hydroxy-phenyl)-6,7-dihydroxy-
isochroman and 1-phenyl-6,7-dihydroxy-isochroman],
present in extra virgin olive oil, inhibited platelet
aggregation and thromboxane release induced by
AA and collagen, but not ADP (Togna et al., 2003).
Beneficial effects have also been reported in human
studies. The significant reduction in plasma TxB2
concentration after an extra virgin olive oil diet
compared to a high-oleic sunflower oil diet was
attributed in part to the greater amount of phenolics
in the former diet (Oubina et al., 2001).
Elucidating the bioavailabilty of phenolic
compounds is essential for understanding whether
the in vitro effects occur in vivo. Indeed, there is
evidence that tyrosol and hydroxytyrosol are
absorbed and metabolised from realistic doses of
extra virgin olive oil (Miro-Casas et al., 2003).
However, the majority of studies have focused on
their subsequent effect on oxidant/antioxidant status
and not on markers of haemostasis. The phenolics in
extra virgin olive oil are potent inhibitors of reactive
oxygen species and they protect against lipid and
lipoprotein oxidation i  vitro (Fito et al., 2000). This
effect may influence the tendency of thrombosis
should the oxidisability of LDL affect platelet function
a  suggested by Siess et al. (1999).
5.7.2. Vitamin E
Vitamin E is an antioxidant nutrient that has the
ability to reduce oxidative damage to LDL and other
lipids. This in itself may influence platelet function
(see above). Moreover, an inhibitory effect of vitamin
E on platelet function has been observed (Steiner,
1999) although the mechanisms of action may not
relate to the antioxidant action of vitamin E but rather
to direct membrane effects (Steiner et al., 1997).
The disadvantage of studying the effects of olive
oil-derived phenolics or vitamin E in vitro is that
bioavailability and metabolism are not accounted for.
Moreover, higher concentrations than those
habitually consumed tend to be employed. Thus, the
needs for human intervention studies rich in (extra
virgin) olive oil are obvious but do not negate the
importance of identifying the active components,
their mechanism of action and efficacy. Both types of
studies are a vital part of maximising the potential
protective effects of (extra virgin) olive oil.
6. CONCLUSION
In the 1970s, Keys et al. (1986) provided
ecological evidence that introduced the concept of a
reduced risk for CHD associated with the traditional
Mediterranean diet and a high intake of MUFA. Since
then, there has been intense investigation to
determine how (extra virgin) olive oil, a key component
of the traditional Mediterranean diet, could contribute to
these cardioprotective effects. Extra virgin olive oil is a
rich source of MUFA and antioxidants. Both
components mediate cardioprotective effects in a
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number of ways, including effects on blood lipids,
inflammation and coagulation. The attenuation of the
thrombotic response by long-term MUFA/olive oil
diets is likely to occur through reduction in platelet
aggregatory response and via a reduction in
postprandial FVII levels. The latter may occur through
actions of MUFA on the formation of chylomicrons,
resulting in generation of larger particles but which
are fewer in number. However, it should be
emphasised that the efficacy and the mechanism of
action of MUFA-rich diets and (extra virgin) olive oil
on determinants of haemostasis are not clear at
present. Nevertheless, based on the evidence to
date, the potential for (extra virgin) olive oil to be
beneficial appears significant.
The traditional Mediterranean diet contains an
abundance of plant foods such as bread, pasta,
vegetables, legumes and fruit with extra virgin olive
oil as the principle source of fat. In many ways, it
meets the dietary guidelines recommended in most
countries; being low in SFA, rich in carbohydrates
and fibre with large amounts of fruit and vegetables.
It is this diet as an entity, and in combination with an
active lifestyle, that is likely to be most beneficial to
health.
On a final point, it is paradoxical that there
appears to be an abandonment of the traditional way
of eating in some Mediterranean areas, whereas
olive oil is now popular with Northern Europeans.
Because the prevalence of CVD risk across
Europe may be changing, an EU-funded project
called IMMIDIET is assessing the contribution of
genes, dietary change and their interaction on any
observed changes in CVD risk factors, including FVII in
subjects from the UK, Italy and Belgium
(www.flair-flow.com/health-docs/ffe58703.html). Diet-
gene interactions were not discussed in this review,
but are likely to explain part of the discrepnacies
between studies and will form an integral part of
future interventions.
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